news, journals and articles from all over the world.
Transplanting cadaver pancreatic islets is a promising therapy for Type 1 diabetes, but a reactivated autoimmunity means low graft viability after five years. Research now shows that a protective coating of two biopolymers can delay allograft and autoimmune-mediated rejection in mouse models of T1D.
Read more
It’s long been thought that having “autoreactive” T cells in the pancreas was a sure sign of type 1 diabetes. Yet a new study led by scientists at La Jolla Institute for Immunology (LJI) shows that even healthy people have these cells lurking in the pancreas—in surprisingly high numbers.
Read more
Insulin pumps are widely used in the management of type 1 diabetes (T1D) and reviews have shown insulin pump therapy to be associated with improved glycemic control, fewer severe hypoglycemia events, and improved quality of life. Yet, non-Hispanic white children (NHW) are more than twice as likely as non-Hispanic Black children (NHB) to use this technology.
Read moreA study led by UC Davis Health researchers uncovered that even one severe episode of diabetic ketoacidosis (DKA) in children newly diagnosed with type 1 diabetes is linked to cognitive problems; and among children with a previous diagnosis, repeated DKA exposure predicted lower cognitive performance after accounting for glycemic control.
Read more
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM). The challenges of managing multiple doses of daily insulin administration, blood glucose monitoring, dietary and exercise requirements, can make self-care difficult and complicate outcomes. Adolescents with T1DM often have poorer diabetes outcomes than others, indicating that glucose control is difficult for them to maintain.
Read more
Researchers at the Georgia Institute of Technology and University of Missouri developed a new microgel drug delivery method that could extend the effectiveness of pancreatic islet transplantations — from several years to possibly the entire lifespan of a recipient.
Read moreA new artificial pancreas system can prevent hypoglycemia—episodes of dangerously low blood sugar—during and after heavy exercise in people with type 1 diabetes, according to a small study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Read more
An artificial pancreas originally developed at the University of Virginia Center for Diabetes Technology safely and effectively manages blood sugar levels in children ages 6 to 13 with type 1 diabetes, a national clinical trial has found.
Read more
Blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes.
Read moreGetting more sleep, and establishing a regular sleep schedule, is a common recommendation for maintaining and improving health, including for people with Type 1 diabetes. Short sleep patterns may affect how the body uses insulin, and irregular sleep schedules can affect glucose through changes in one’s circadian rhythm or biological clock.
Read more
Researchers have discovered a new drug candidate that offers a major advance to treat diabetes. Tested on human and mouse pancreatic islets, mouse and rat cell cultures and animal models of Type 1 and Type 2 diabetes, the drug significantly improved four detrimental characteristics of diabetes.
Read more
Albert Einstein College of Medicine has received a $9.5 million, five-year grant from the National Institutes of Health (NIH) to support the Einstein-Mount Sinai Diabetes Research Center (ES-DRC). The multi-institutional center is a leader in basic, translational, clinical, and community-based research and training in type 1 and type 2 diabetes, obesity, and other metabolic disorders.
Read more